30 closest matches · ranked by relevance
Acute Episode of Overt Hepatic Encephalopathy · Hepatic Encephalopathy
Primary: Percentage of Participants in Each HE Stage — 11; 6; 30; 40 percentage of participants
Overt Hepatic Encephalopathy
Primary: Time to Overt Hepatic Encephalopathy (OHE) Resolution Determined Using the Hepatic Encephalopathy Grading Instrument (HEGI), Defined as HEGI Score < 2 — 36.1; 21.1…
Cirrhosis · Hepatic Encephalopathy
Primary: Number of Participants Who Experienced Serious Adverse Events up to Week 6 — 2; 0 Participants
Hepatic Encephalopathy
Primary: Complete Reversal — 80 percentage of participants
Hepatic Encephalopathy · Cirrhosis
Primary: Number of Participants Reporting a First Breakthrough HE Episode — 28; 15 Participants — p=0.0359
Cirrhosis · Hepatic Encephalopathy
Primary: Part A: The Rate of AEs and Tolerability of HPN-100 — 11; 9; 7; 4 Subjects
Cirrhosis · Ascites · Liver Diseases
Primary: Overall Participant Retention Rate Based on Proportion of Participants Who Complete All Study Visits — 10 Participants
Hepatic Encephalopathy
Primary: Time To The First Breakthrough Overt HE Episode — 13; 20; 4; 23 events — p=<0.0001
Hepatic Encephalopathy
Primary: Percentage of Slow Wave Sleep and REM Sleep — 56 percentage of total sleep time per 24h
Acute Liver Failure · Acute Liver Injury
Primary: Number of Participants That do Not Tolerate the Administered Dose and Had Grade 3 or 4 Treatment Emergent Adverse Events as a Measure of Safety and Tolerability — 0; 0…
Hepatic Encephalopathy
Primary: Number Of Participants Reporting A Non-serious Adverse Event Or A Serious Adverse Event — 78; 15; 158; 49 Participants
Cirrhosis · Hepatic Encephalopathy
Primary: Serious Adverse Events Related to FMT — 0; 0; 0; 0 Participants
Hepatic Encephalopathy
Primary: Driving Performance — 7.6; 5.5 raw number of driving errors
Hepatic Cirrhosis · Hepatic Encephalopathy (HE)
Primary: Ammonia Plasma Levels at Baseline and Day 5 — 70.4; 91.4; 92.6; 78.1 μmol/L
Hyperammonemia
Primary: Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs) — 6; 6; 7; 8 participants
Alcoholic Liver Disease
Primary: Liver Enzymes(ALT) — 66; 48 IU/L
Cirrhosis
Primary: Short Form-8 Health Survey (SF-8) at 28 Days — 8.1; 6.55; 70.9; 63.84 score on a scale — p=0.6
Propionic Acidemia, Type I and/or Type II · Methylmalonic Acidemia · Carbamoyl-Phosphate Synthase I Deficiency Disease
Primary: Time to the Primary Outcome (Earlier of Ammonia <50 µmol/L or Hospital Discharge) — 1.37; 0.79 Hazard Ratio
Decompensated Cirrhosis and Ascites
Primary: Time to Liver Transplantation or Death Through 1 Year After Randomization: Percentage of Participants With an Event — 33.5; 38.6 percentage of participants — p=0.17
Acute Alcoholic Hepatitis
Primary: 180 Days Mortality — 17; 22; 0 Participants — p=.30
Cirrhosis
Primary: Body Weight — -1.14; -1.37 kg
Cirrhosis
Primary: Body Weight — -0.76; -2.97; -0.05 Kg
Liver Failure, Acute on Chronic
Primary: 28-day Mortality,28-day Liver-transplantation Free Mortality& 28-day Liver Transplantation Rate — 74; 124; 74 Participants
End Stage Liver Disease
Primary: Patient Satisfaction — 45 Participants
Psychosis · Schizophrenia · Schizo Affective Disorder
Primary: Change in Cerebral Blood Flow (CBF) — -2.21; -3.83; -1.29 mL / (100g * min)
Hepatitis, Alcoholic
Primary: Gastrointestinal Safety Endpoints — 15; 27; 7; 14 Incidents
Acute Liver Failure
Primary: Peak Percent Dose Recovery (PDR) Value — 10.2; 1.9 percentage per hour
Nonconvulsive Status Epilepticus · Subclinical Seizure · Altered Mental Status
Primary: Time Difference Between EEG Cap and Standard EEG Results Reporting — 103.4 minutes — p=0.0005
Hepatic Encephalopathy · Cirrhosis · Portosystemic Encephalopathy
Primary: Number of Participants With an Improvement of 1 or More in HE Grade at 24 Hours — 21; 13 participants
Cirrhosis
Primary: Body ｗeight — -1.95; -0.44 Kg — p=<0.0001